Ann: Regeneus receives upfront payment of US$5.5m from AGC, page-22

Thanks, I didn't know that AGC was a part of the Mitsubishi Group of companies! Very interesting imo.

Progenza will be a key part of AGC’s strategic plan
AGC is a Tokyo-headquartered multinational manufacturer that is part of the influential Mitsubishi group of companies, which are estimated to account for ~10% of Japan’s GDP. AGC generated net sales in 2015 of ¥1,326bn and an operating profit of ¥71bn. Glass accounted for 52% of revenue, while the chemicals business segment, which includes the life sciences business unit, generated 22% of revenue.
As part of a 10-year strategic vision established in February 2016, AGC has designated life sciences as one of three high value-added strategic businesses where it will aim for high growth in targeted markets. It has made a number of acquisitions to help it achieve this goal.
On 19 December 2016, AGC acquired CMC Biologics (CMC), a Danish company with manufacturing facilities in Copenhagen in Denmark, and in Seattle and Berkeley in the US, for ~US$510m. CMC provides contract development and manufacturing organisation (CDMO) services for the manufacture of monoclonal antibodies, coagulation factors and other therapeutic proteins, including its proprietary CHEF1 expression system for production in mammalian cells. In September 2016, AGC acquired Biomeva, based in Heidelberg, Germany, undertakes contract manufacturing of biopharmaceuticals using microbial expression technology.